Cencora, Inc. $COR Shares Sold by Royal Bank of Canada

Royal Bank of Canada cut its stake in shares of Cencora, Inc. (NYSE:COR) by 47.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 745,366 shares of the company’s stock after selling 674,141 shares during the quarter. Royal Bank of Canada’s holdings in Cencora were worth $234,150,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Kemnay Advisory Services Inc. acquired a new stake in shares of Cencora during the fourth quarter worth $25,000. Oakworth Capital Inc. purchased a new position in Cencora in the 4th quarter worth about $26,000. Elyxium Wealth LLC purchased a new position in Cencora in the 4th quarter worth about $27,000. Archer Investment Corp raised its holdings in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares during the period. Finally, Motiv8 Investments LLC purchased a new stake in Cencora during the fourth quarter valued at about $29,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of COR opened at $318.54 on Thursday. The company has a market capitalization of $61.97 billion, a price-to-earnings ratio of 24.43, a P/E/G ratio of 1.77 and a beta of 0.58. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The business’s 50-day moving average is $287.66 and its 200-day moving average is $315.79.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the prior year, the business posted $4.42 earnings per share. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts expect that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora declared that its Board of Directors has approved a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is 18.40%.

Insider Activity at Cencora

In related news, Director Lauren M. Tyler purchased 550 shares of the stock in a transaction dated Monday, June 22nd. The shares were acquired at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the acquisition, the director directly owned 4,359 shares in the company, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.38% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have commented on COR shares. Morgan Stanley set a $342.00 target price on shares of Cencora in a report on Friday, May 8th. Barclays reduced their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a research report on Wednesday, June 10th. Citigroup decreased their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. UBS Group lifted their price objective on shares of Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $367.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.